Vertex Pharmaceuticals Incorporated: all 295 studies

Page 2 of 3. Open to participants first (23), then studies with results posted, then the rest; newest registration first within each.

• A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationCompletedNCT02508207Phase 2Results posted
• A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to IvacaftorCompletedNCT02412111Phase 3Results posted
• A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) MutationCompletedNCT02392234Phase 3Results posted
• Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung DiseaseCompletedNCT02390219Phase 3Results posted
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With IvacaftorCompletedNCT02347657Phase 3Results posted
• A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes MellitusTerminatedNCT02239354Phase 1/2Results posted
• Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label ExpansionCompletedNCT02070744Phase 2Results posted
• MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy SubjectsCompletedNCT02013388Phase 1Results posted
• Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating MutationCompletedNCT01946412Phase 3Results posted
• A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic FibrosisCompletedNCT01931839Phase 3Results posted
• Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationCompletedNCT01897233Phase 3Results posted
• A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR MutationCompletedNCT01807949Phase 3Results posted
• A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR MutationCompletedNCT01807923Phase 3Results posted
• Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR MutationCompletedNCT01746784Phase 1Results posted
• Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR MutationCompletedNCT01707290Phase 3Results posted
• Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating MutationCompletedNCT01705145Phase 3Results posted
• An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C VirusTerminatedNCT01701063Phase 1/2Results posted
• Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR FunctionCompletedNCT01685801Phase 2Results posted
• Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating MutationCompletedNCT01614470Phase 3Results posted
• Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)CompletedNCT01614457Phase 3Results posted
• Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) MutationCompletedNCT01531673Phase 2Results posted
• An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant PatientsTerminatedNCT01467505Phase 2Results posted
• Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis CTerminatedNCT01467492Phase 4Results posted
• A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)TerminatedNCT01467479Phase 3Results posted
• Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC GenotypeTerminatedNCT01459913Phase 3Results posted
• A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy SubjectsCompletedNCT01339897Phase 1Results posted
• Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild AsthmaCompletedNCT01316315Phase 1/2Results posted
• Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D MutationCompletedNCT01262352Phase 2Results posted
• Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR MutationCompletedNCT01225211Phase 2Results posted
• Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D MutationCompletedNCT01161537Phase 2Results posted
• Safety and Tolerability Study of N6022 in Healthy SubjectsCompletedNCT01147406Phase 1Results posted
• Rollover Study of VX-770 in Cystic Fibrosis SubjectsCompletedNCT01117012Phase 3Results posted
• Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIVCompletedNCT00983853Phase 2Results posted
• Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR MutationTerminatedNCT00953706Phase 2Results posted
• Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D MutationCompletedNCT00909727Phase 3Results posted
• Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D MutationCompletedNCT00909532Phase 3Results posted
• Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene MutationCompletedNCT00865904Phase 2Results posted
• A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral ResponseCompletedNCT00758043Phase 3Results posted
• A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)CompletedNCT00627926Phase 3Results posted
• A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to TherapyCompletedNCT00535847Phase 2Results posted
• Safety Study of Ivacaftor in Subjects With Cystic FibrosisCompletedNCT00457821Phase 2Results posted
• A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)CompletedNCT00420784Phase 2Results posted
• Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis CCompletedNCT00372385Phase 2Results posted
• Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis CCompletedNCT00336479Phase 2Results posted
• Drug-Drug Interaction Study of Atumelnant in Healthy ParticipantsCompletedNCT07570082Phase 1
• Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy ParticipantsCompletedNCT07570069Phase 1
• Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female ParticipantsCompletedNCT07378865Phase 1
• Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy ParticipantsCompletedNCT07349394Phase 1
• A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian ParticipantsCompletedNCT07221084Phase 1
• Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)Active, not recruitingNCT07161037Phase 2
• A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid TumorsActive, not recruitingNCT07129252Phase 1/2
• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenActive, not recruitingNCT07087054Phase 3
• Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy ParticipantsCompletedNCT07074327Phase 1
• A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy ParticipantsCompletedNCT07022119Phase 1
• A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept PresentationsCompletedNCT07010406Phase 1
• A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive SurgeriesCompletedNCT06887972Phase 4
• A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected SurgeriesCompletedNCT06887959Phase 4
• A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral DoseCompletedNCT06886269Phase 1
• A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet FormulationCompletedNCT06861413Phase 1
• A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult PanelistsCompletedNCT06834009Phase 1
• Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female ParticipantsCompletedNCT06820307Phase 1
• Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without ComorbiditiesCompletedNCT06794996Phase 2
• Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT06747572
• Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)Active, not recruitingNCT06696443Phase 3
• A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a BunionectomyCompletedNCT06619847Phase 2
• A Phase 1 Dose Escalation Study of VX-973 in Healthy ParticipantsCompletedNCT06615570Phase 1
• Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)Active, not recruitingNCT06564142Phase 3
• Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic ImpairmentCompletedNCT06529796Phase 1
• Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy AdultsCompletedNCT06523595Phase 1
• A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993CompletedNCT06508762Phase 1
• Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)CompletedNCT06506773
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and OlderActive, not recruitingNCT06460506Phase 3
• A Microneurography Study of NaV1.8 Inhibition in Healthy AdultsCompletedNCT06420765Phase 1
• A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy AdultsCompletedNCT06394167Phase 1
• A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy AdultsCompletedNCT06392659Phase 1
• A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy ParticipantsCompletedNCT06345755Phase 1
• A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of SuzetrigineCompletedNCT06336096Phase 1
• A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet FormulationCompletedNCT06312787Phase 1
• A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)CompletedNCT06299709Phase 1
• A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult PanelistsCompletedNCT06299696Phase 1
• A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993CompletedNCT06226454Phase 1
• A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)Active, not recruitingNCT06185764Phase 1/2
• Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)CompletedNCT06176196Phase 2
• Evaluation of VX-828 in Healthy Participants and in Participants With Cystic FibrosisCompletedNCT06154447Phase 1
• Single and Multiple-Ascending Dose Study of CRN04894 in Healthy VolunteersCompletedNCT06048887Phase 1
• A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147CompletedNCT05955872Phase 1
• Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC GenotypeWithdrawnNCT05951205Phase 3
• An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy ParticipantsCompletedNCT05867147Phase 1
• A Phase 1 Dose Escalation Study of VX-973 in Healthy AdultsCompletedNCT05866055Phase 1
• A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal ImpairmentCompletedNCT05865171Phase 1
• A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548CompletedNCT05851157Phase 1
• A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy ParticipantsCompletedNCT05818852Phase 1
• A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's SyndromeCompletedNCT05804669Phase 1/2
• A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 DiabetesActive, not recruitingNCT05791201Phase 1/2
• An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)CompletedNCT05757570Phase 1/2
• An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesActive, not recruitingNCT05732402Phase 1/2
• A Phase 1, First-in-human Study of VX-668CompletedNCT05727800Phase 1
• Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal ImpairmentCompletedNCT05704556Phase 1
• A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)CompletedNCT05668741Phase 1/2
• A Phase 1 Dose Escalation Study of VX-993 in Healthy ParticipantsCompletedNCT05653323Phase 1

← Vertex Pharmaceuticals Incorporated overview and focus areas